eXoZymes Inc.

Nov 13, 2026

eXoZymes to Host Third Quarter 2026 update Conference Call on Thursday, November 19, 2026

eXoZymes Inc. will host a webinar on November 19, 2026, at 5:00 PM ET to discuss its third quarter results. CEO Michael Heltzen and the management team will review recent developments and upcoming milestones. A press release detailing the results will be issued before the call.

Oct 21, 2026

eXoZymes CEO to Discuss Commercialization, Key Milestones, and Potential Catalysts in Fireside Chat with Water Tower Research

eXoZymes CEO Michael Heltzen will participate in a fireside chat hosted by Water Tower Research on October 22, 2026. The discussion will cover the company's cell-free biomanufacturing technology and its first product, NCT, aimed at nutraceutical and pharmaceutical markets. Heltzen will also address key milestones and potential catalysts for growth.

eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT

eXoZymes has partnered with Curia Global to scale its NCT manufacturing process from pilot to commercial levels. The initiative, set to begin in Q4 2026, includes technology transfer and process validation at Curia's facilities in Spain and Italy. This collaboration aims to establish a reliable supply chain for NCT's market introduction planned for 2027.

Jun 24, 2026

EXOZFDA Updates

eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery

eXoZymes Inc. has received a $2 million grant from the NIH to advance its cannabinoid analogs for drug discovery. This funding will support the company's efforts to develop new pharmaceutical assets and validate its capabilities in producing rare cannabinoids. The project is set to commence on July 1, 2026, marking a significant step in eXoZymes' growth.

Jun 17, 2026

▼ -14.7%on this newsshared move

eXoZymes Inc. Announces Closing of $6 Million Public Offering

eXoZymes Inc. has successfully closed a $6 million public offering, which includes the sale of common stock and warrants. The gross proceeds are intended to support the development of the company's AI-enhanced enzyme technology and related commercialization activities. Despite the positive implications for funding, the press release includes caution regarding potential risks to future performance and the lack of liquidity for the warrants sold. The company aims to pave the way for advancements in sustainable biomanufacturing.

eXoZymes, Inc. Announces Pricing of Public Offering of Common Stock and Warrants

eXoZymes Inc. has announced the pricing of its public offering of units, consisting of shares of common stock and warrants, expected to raise around $5.33 million. The offering is set to close on June 9, 2026, pending customary closing conditions. The company plans to utilize the net proceeds for advancing its N-trans-caffeoyltyramine opportunities, as well as research and development, working capital, and capital expenditures. However, potential investors should be aware of the associated risks, including the lack of a trading market for the warrants and the conditions under which the warrants may reset.

Mar 26, 2026

eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026

eXoZymes Inc. will host a webinar on March 31, 2026, to discuss its fourth quarter and full year 2025 results. CEO Michael Heltzen will lead the call, which will cover recent developments and future milestones. A press release detailing the results will be issued prior to the call, and investors can pre-register for the event.

Jan 29, 2026

advancing commercial readiness with profound production metrics on initial NCT pilot run Angeles, CA -- January 29, 2026 -- Today, eXoZymes Inc. (NASDAQ: EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that

eXoZymes Inc. has reported successful results from its first 100-liter pilot production run of N-trans-caffeoyltyramine (NCT), achieving high performance metrics including a 99% reaction conversion rate and 90% yield. The use of AI-enhanced enzymes allowed for a scalable and robust biomanufacturing process, contradicting conventional scaling challenges typically seen in biological systems. This pilot marks a significant step towards commercializing a sustainable supply chain for NCT, as the company prepares to engage partners in formulation development and application testing. eXoZymes aims to refine their manufacturing techniques and expand production capabilities in 2026.

Dec 11, 2025

eXoZymes achieves 100 scale-up of NCT production using exozymes, demonstrating near-perfect feedstock conversion.

eXoZymes Inc. has announced a significant milestone by achieving a 100-fold scale-up in producing N-trans-caffeoyltyramine (NCT) through its advanced exozyme-based platform. This process boasts an exceptional conversion efficiency exceeding 99% from feedstock to product, paving the way for future biomanufacturing innovations. The achievement underscores the potential of cell-free enzyme systems to operate reliably at scale, overcoming challenges associated with traditional manufacturing methods. Further technical details and insights from the production process are expected in early 2026.

selected as core industry partner in $9M NSF-funded initiative to advance modular cell-free biomanufacturing CA - June 26, 2025 - Today, eXoZymes Inc. (NASDAQ: EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that

eXoZymes Inc. has been selected as a core industry partner in the $9M NSF-funded Meta-PURE initiative aimed at advancing modular cell-free biomanufacturing. The project is led by Georgia Tech and will develop standardized, interoperable modules for diverse applications in synthetic biology. eXoZymes will contribute a cell-free ATP-generating module and a production module for the fragrance compound santalene. The initiative aims to enhance the scalability and accessibility of biomanufacturing technologies over a three-year period.

Apr 2, 2025

eXoZymes Provides Fourth Quarter and Full Year 2024 Update to Host Conference Call Today at 4:30PM Eastern

eXoZymes Inc. has provided an operational update for the fourth quarter and full year of 2024, emphasizing its focus on commercialization through partnerships and innovative AI-engineered enzymes. The company successfully completed its IPO and began trading on Nasdaq in late 2024, despite the challenging fundraising environment. CEO Heltzen highlighted ongoing initiatives to enhance the biomanufacturing process and the importance of achieving commercial applications.

Apr 2, 2025

eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO CA - April 2, 2025 - Today, eXoZymes Inc. (NASDAQ: EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that

eXoZymes Inc. announced the appointment of Damien Perriman as the new Chief Commercial Officer (CCO) to support its growth in biomanufacturing. With over two decades of experience in commercializing biotechnologies across multiple sectors, Perriman aims to enhance the company's efforts in scaling and commercializing biosolutions. This strategic hire is part of eXoZymes' commitment to pioneering sustainable alternatives in the chemical production industry through its AI-engineered enzymes.

Nov 12, 2024